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CYTOKINES play critical roles in the immune re-
sponse, particularly in the self-defense system. Ac-
tivated human monocyte/macrophage is a major source of 
interleukin-6 (lL-6) and tumor necrosis factor-alpha (TNF-
a). I Interleukin-2 HL-2) is released primarily by activated 
T lymphocytes following antigen presentation.2 We con-
ducted a study to monitor various cytokines (IL-6. TNF-a, 
and IL-2) after small bowel transplantation and evaluated 
whether or not the serum cytokine level could reflect the 
rejection of human small bowel allograft. 
MATERIALS AND METHODS 
Three patients (two adults. one child) undergoing small bowel 
transplantation with FK 506 at the University Hospital of Pitts-
burgh, were the subjects of this study. One of them received small 
bowel allograft alone and the others received liver and small 
bowel allografts simultaneously. Their serum levels of IL-6. 
TNF-a, and IL-2 were monitored daily (from preopcration day to 
29 to 42 days) by a two-step sandwich enzyme immunoassay 
method using an enzyme-linked immunosorbent (ELISA) kit 
(R&D System Inc. Minneapolis. Minn). Sixteen serial biopsies of 
allografts were performed during this cytokine-monitoring period. 
RESULTS 
There were clinically and pathologically six episodes of 
acute cellular rejection (ACR) in three patients during the 
monitoring periods. As shown in Fig 1, there were three 
episodes of ACR in a patient during the cytokine-monitor-
ing period and coincidental elevation of IL-6 was noted in 
all three instances. Although there was an elevation of IL-2 
or TNF-a during the monitoring period. it did not neces-
sarily reflect the rejection episodes. The other two cases 
demonstrated a similar monitoring pattern (data not 
shown). Serum levels ofIL-6, TNF-a, and IL-2 feU rapidly 
following antirejection therapy, a bolus of solumedrol. 
DISCUSSION AND CONCLUSION 
IL-6 and TNF-a (pleiotropic cytokines) regulate immune 
responses and acute phase reactions. I This study indicates 
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Fig 1. Serum levels of IL-G, TNF-a, and IL-2 in an adult patient 
with small bowel and liver transplantation. There was no evidence 
of bacterial or viral infection in this period. 
that elevation of IL-6 and other cytokines during the ACR 
of small bowel or liver allograft probably reflects a part of 
acute phase reaction that occurred in a transplanted recip-
ient. In conclusion. these results suggest that the daily 
monitoring of serum levels of TNF-a. IL-2. and particu-
larly IL-6 is useful in the diagnosis of graft rejection. and is 
also helpful in evaluation of the therapeutic effect of 
antirejection therapy. 
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